相似文献
1
Predictors of benefit in colorectal cancer treated with cetuximab: are we getting "Lost in TranslationAL"?
J Clin Oncol. 2010 Apr 10;28(11):e173-4; author reply e175-6. doi: 10.1200/JCO.2009.26.6148. Epub 2010 Feb 22.
2
KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature.
J Clin Oncol. 2008 May 1;26(13):2228-30; author reply 2230-1. doi: 10.1200/JCO.2007.15.9186.
3
[Mutation of EGFR signaling pathway and therapy for metastatic colorectal cancer].
Gan To Kagaku Ryoho. 2010 May;37(5):791-4.
4
[Biology applied to cancer treatments: the example of colorectal cancer].
Rev Prat. 2010 Oct 20;60(8):1100-2.
5
Should KRAS mutations be considered an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab?
J Clin Oncol. 2008 May 20;26(15):2600; author reply 2601-2. doi: 10.1200/JCO.2008.16.8195.
6
To give or not to give anti-epidermal growth factor receptor (EGFR) monoclonal antibodies to patients with KRAS G13D mutation in advanced colorectal cancer.
Clin Colorectal Cancer. 2012 Jun;11(2):85-7. doi: 10.1016/j.clcc.2011.10.005. Epub 2011 Dec 9.
7
Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.
J Clin Oncol. 2009 Dec 10;27(35):5924-30. doi: 10.1200/JCO.2008.21.6796. Epub 2009 Nov 2.
8
Colorectal cancer: cetuximab, KRAS, BRAF, PIK3CA mutations and beyond.
Expert Rev Gastroenterol Hepatol. 2010 Oct;4(5):525-9. doi: 10.1586/egh.10.62.
9
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
J Clin Oncol. 2008 Dec 10;26(35):5705-12. doi: 10.1200/JCO.2008.18.0786. Epub 2008 Nov 10.
10
Chemotherapy and immunotherapy in metastatic colorectal cancer.
N Engl J Med. 2009 May 14;360(20):2135; author reply 2135-6.
引用本文的文献
1
Chemotherapy plus bevacizumab as an optimal first-line therapeutic treatment for patients with right-sided metastatic colon cancer: a meta-analysis of first-line clinical trials.
ESMO Open. 2020 Mar;4(Suppl 2). doi: 10.1136/esmoopen-2019-000605.
2
EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan.
Target Oncol. 2014 Sep;9(3):205-14. doi: 10.1007/s11523-013-0284-7. Epub 2013 Jul 3.
Zotero 插件